Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3618081 | 0.86 | RIPK1 (0.53) | RIPK1TAAR1TRPA1AOC3 | |
| SCHEMBL6280516 | 0.85 | RIPK1 (0.67) | RIPK1TAAR1TRPA1AOC3 | |
| SCHEMBL5213988 | 0.82 | RIPK1 (0.64) | RIPK1TAAR1TRPA1AOC3 | |
| Lithium SCHEMBL30777534 | 0.82 | RIPK1 (0.64) | RIPK1TAAR1TRPA1AOC3 | |
| SCHEMBL8159872 | 0.80 | TAAR1 (0.58) | RIPK1TAAR1TRPA1AOC3 | |
| SCHEMBL583097 | 0.80 | TAAR1 (0.58) | RIPK1TAAR1TRPA1AOC3 | |
| SCHEMBL2736634 | 0.80 | TAAR1 (0.58) | RIPK1TAAR1TRPA1AOC3 | |
| SCHEMBL14658424 | 0.79 | ACHE (0.46) | RIPK1 | |
| SCHEMBL17451533 | 0.79 | RIPK1 (0.55) | RIPK1TAAR1TRPA1AOC3 | |
| SCHEMBL7041633 | 0.79 | RIPK1 (0.55) | RIPK1TAAR1TRPA1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109854-A1 | CURABLE RESIN COMPOSITION, AND CURED PRODUCT THEREOF | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2026-04-23 | — | — | US | disclosed |
| US-20260109853-A1 | CURABLE RESIN COMPOSITION AND CURED PRODUCT OF SAME | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2026-04-23 | — | — | US | disclosed |
| EP-4508101-B1 | PROCESS FOR MANUFACTURING OF POLYISOBUTENE SUCCINIC ANHYDRIDES | BASF SE (DE) | 2026-03-25 | — | — | EP | disclosed |
| EP-4709518-A1 | PROCESS FOR THE PREPARATION OF POLYISOBUTENE FROM OLEFINS FROM ISOBUTANOL OBTAINED FROM MIXED GUERBET REACTION OF ETHANOL AND METHANOL | BASF SE (DE) | 2026-03-18 | — | — | EP | disclosed |
| EP-4667447-A1 | PROCESS FOR THE PREPARATION OF POLYISOBUTENE FROM BIO-BASED OLEFINS FROM PRIMARY ALCOHOL | BASF SE (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-20250250382-A1 | PROCESS FOR MANUFACTURING OF POLYISOBUTENE SUCCINIC ANHYDRIDES | BASF SE (DE) | 2025-08-07 | — | — | US | disclosed |
| US-20250250403-A1 | PROCESS FOR MANUFACTURING OF POLYISOBUTENE SUCCINIC ANHYDRIDES | BASF SE (DE) | 2025-08-07 | — | — | US | disclosed |
| US-20250179224-A1 | MEDIUM MOLECULAR POLYISOBUTENE WITH A CERTAIN DISTRIBUTION OF DOUBLE BOND ISOMERS | BASF SE (DE) | 2025-06-05 | — | — | US | disclosed |
| US-20250145742-A1 | MEDIUM MOLECULAR POLYISOBUTENE WITH A HIGH CONTENT OF CERTAIN DOUBLE BOND ISOMERS | BASF SE (DE) | 2025-05-08 | — | — | US | disclosed |
| WO-2025082909-A1 | PROCESS FOR IMPROVING THE STABILITY OF POLYISOBUTENES | BASF SE (DE) | 2025-04-24 | — | — | WO | disclosed |
| US-6800645-B1 | INHIBIT PRODUCTION OR PHYSIOLOGICAL EFFECTS OF TNF, INHIBIT CYCLIC AMP PHOSPHODIESTERASE | AVENTIS PHARMA LIMITED (GB) | 2004-10-05 | — | — | US | disclosed |
| US-20020173527-A1 | Substituted azabicyclic compounds | ASTLES PETER CHARLES (GB) | 2002-11-21 | — | — | US | disclosed |
| US-6303600-B1 | USED IN THERAPY OF DISEASE STATES ASSOCIATED WITH PROTEINS THAT MEDIATE CELLULAR ACTIVITY | RHONE-POULENC RORER LIMITED (GB) | 2001-10-16 | — | — | US | disclosed |
| EP-0934307-A1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | RHONE-POULENC RORER LIMITED (GB) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998005327-A1 | SUBSTITUTED AROMATIC COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| WO-1997048697-A1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | RHONE-POULENC RORER LIMITED (GB) | 1997-12-24 | — | — | WO | disclosed |
| US-5262420-A | Phenylalkylpyridines | IDEMITSU KOSAN CO., LTD. (JP) | 1993-11-16 | — | — | US | disclosed |
| US-4987132-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-01-22 | — | — | US | disclosed |
| CN-1030415-A | Saturated heterocycle carboxamide derivatives and its preparation method | YAMANOUCHI PHARMA CO LTD (JP) | 1989-01-18 | — | — | CN | disclosed |
| EP-0279681-A2 | Saturated heterocyclic carboxamide derivatives | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1988-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109854-A1 | CURABLE RESIN COMPOSITION, AND CURED PRODUCT THEREOF | MLLT1, CRBN, POT1 | RIPK1 1464/4885TAAR1 4109/4885TRPA1 909/4885 |
| US-20020173527-A1 | Substituted azabicyclic compounds | CBR1, NOX1, POR | RIPK1 3390/4885TAAR1 661/4885TRPA1 4125/4885 |
| US-20260109853-A1 | CURABLE RESIN COMPOSITION AND CURED PRODUCT OF SAME | PSMA1, PSMB10, RAD51 | RIPK1 1996/4885TAAR1 3193/4885TRPA1 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.